FREE Account Opening + No Clearing Fees

Infinium Pharma NSE SME IPO review (May apply)

Review By Dilip Davda on March 25, 2023

•    IPL is an integrated Pharma and Healthcare segment company with niche products.
•    It has posted consistent growth in its top and bottom lines for the reported periods.
•    However, its FY23 super performance so far raises concern over enjoying such margins going forward.
•    Based on its recent earnings, the issue appears fully priced.
• Well-informed investors may consider investment for the medium to long term. 

Infinium Pharmachem Ltd. (IPL) was incorporated with the objective of manufacturing and supplying various pharma-related chemicals, bulk drugs, pharma intermediates etc. Accordingly, the Company is dealing specifically and mainly in manufacturing and supplying of Iodine Derivatives, Pharma Intermediates and Active Pharmaceutical Ingredients (APIs). The Company was formed with a vision to be a globally integrated and admired Pharmaceutical & Healthcare Company.

IPL undertakes Contract Research and Manufacturing Services (CRAMS) to provide customized and fully confidential solutions to its clients. Today, the Company's manufacturing capabilities and technical expertise have efficiently catered to numerous industries such as Pharmaceutical & Biotech, Specialty & Performance Chemicals, Agrochemicals, Human Health, Animal Health, Cosmetics, Sanitation, Electrical, Electronics and much more. 

The Company currently provides the widest range of Iodine derivatives in the market, with more than 250+ intermediates and 15+ APIs. All its products are developed to meet challenging demands, superior quality, performance and various other commercial requirements across industries. It has developed and maintained long-term healthy relationships with all its clients, including Pharmaceutical, Biotech and Fine Chemical companies and its products reach out to over 250+ clients globally. It has formed a Subsidiary Company in the name of Infinium Green Energy Private Limited on June 06th, 2022. The Company also formed a foreign Subsidiary as a Joint Venture (JV) with Shanghai Witofly Chemical Co. Ltd., in the name of Shanghai Tajilin Industrial Co. Ltd., in the People's Republic of China in the year 2019. As of December 31, 2022, it had 89 employees on its payroll. 

The company is coming out with a maiden IPO of 1875000 equity shares of Rs. 10 each at a fixed price of Rs. 135 per share to mobilize Rs.25.26 cr. The issue opens for subscription on March 31, 2023, and will close on April 05, 2023. The minimum application is to be made for 1000 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on NSE SME Emerge. The issue constitutes 26.95% of the post-issue paid-up capital of the company. IPL is spending Rs. 0.63 cr. for this IPO process and from the net proceeds, it will utilize Rs. 1.13 cr. for marketing and branding, Rs. 3.92 cr. for repayment of certain borrowings, and Rs. 5.05 cr. for expansion of existing unit, Rs. 10.10 cr. for working capital, and Rs. 4.43 cr. for general corporate purposes.

Swastika Investmart Ltd. is the sole lead manager as well as the market maker and Bigshare Services Pvt. Ltd. is the registrar of the issue. 

Having issued initial equity shares at par, the company issued further equity shares in the price range of Rs. 45 and Rs. 110 per share between March 2010 and March 2017. It has also issued bonus shares in the ratio of 1 for 1 in March 2014 and 4 for 1 in June 2022. The average cost of acquisition of shares by the promoters is Rs. 2.71, Rs. 2.89, and Rs. 3.80 per share. 

Post-IPO, IPL's current paid-up equity capital of Rs. 5.08 cr. (5083060 shares) will stand enhanced to Rs. 6.96 cr. (6958060 shares).  Based on the IPO pricing, the company is looking for a market cap of Rs. 93.93 cr. 

On the financial performance front, for the last three fiscals, IPL has (on a consolidated basis) posted a turnover/net profit of Rs. 39.42 cr. / Rs. 0.87 cr. (FY20), Rs. 71.15 cr. / Rs. 2.73 cr. (FY21), and Rs. 100.05 cr. / Rs. 6.69 cr. (FY22). For H1 of FY23 ended on September 30, 2022, it earned a net profit of Rs. 6.00 cr. on a turnover of Rs. 79.85 cr. Thus it has posted growth in its top and bottom lines for the reported periods. Its PAT margins have improved from 2.82% as of March 31, 2020, to 8.49% as of September 30, 2022. However, the many-fold jump in the bottom line for the first half of FY23 raises eyebrows and concerns over sustainability.

For the last three fiscals, the company has reported an average EPS of Rs. 40.50 and an average RoNW of 39.9%. The issue is priced at a P/BV of 4.55 based on its NAV of Rs. 29.69 as of September 30, 2022, and at a P/BV of 1.87 based on its post-IPO NAV of Rs. 72.24 per share. 

If we annualize FY23 earnings and attribute it to post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 7.83 whereas on the basis of FY22 earnings the P/E stands at 14.05, thus the IPO appears fully priced.

The company has not declared any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy post-listing, based on its financial performance and future prospects. 

As per the offer document, the company has shown Samrat Pharmachem Ltd. as their listed peer. It is trading at a P/E of 5.12 (as of March 24, 2023). However, they are not truly comparable on an apple-to-apple basis.  

This is the 5th mandate from Swastika Investmart in the last three fiscals (including the ongoing one). Out of the last 4 listings, 1 opened at discount, 1 at par and the rest at premiums ranging from 4.17% to 36.25% on the listing date.

Conclusion / Investment Strategy

IPL is in the pharma and healthcare segment and has posted growth in its top and bottom lines for the reported periods. Super earnings for FY23 H1 raise eyebrows and concern over the sustainability of such margins going forward. Well-informed investors may park funds for medium to long-term rewards.

Review By Dilip Davda on March 25, 2023

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

Infinium Pharmachem IPO FAQs

  1. 1. Why Infinium Pharmachem IPO?

    The initial public offer (IPO) of Infinium Pharmachem Limited offers an early investment opportunity in Infinium Pharmachem Limited. A stock market investor can buy Infinium Pharmachem IPO shares by applying in IPO before Infinium Pharmachem Limited shares get listed at the stock exchanges. An investor could invest in Infinium Pharmachem IPO for short term listing gain or a long term.

  2. 2. How is Infinium Pharmachem IPO?

    Read the Infinium Pharmachem IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. Infinium Pharmachem IPO what should investors do?

    Infinium Pharmachem IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Infinium Pharmachem IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Infinium Pharmachem IPO good?

    Our recommendation for Infinium Pharmachem IPO is to subscribe for long term.

  5. 5. Is Infinium Pharmachem IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe for long term to the Infinium Pharmachem IPO.

  6. 6. When will Infinium Pharmachem IPO allotment status?

    The Infinium Pharmachem IPO allotment status will be available on or around April 11, 2023. The allotted shares will be credited in demat account by April 13, 2023. Visit Infinium Pharmachem IPO allotment status to check.

  7. 7. When will Infinium Pharmachem IPO list?

    The Infinium Pharmachem IPO will list on Monday, April 17, 2023, at NSE SME.